Locally advanced and unresectable cutaneous squamous cell carcinoma: Outcomes of concurrent cetuximab and radiotherapy Journal Article

Authors: Samstein, R. M.; Ho, A. L.; Lee, N. Y.; Barker, C. A.
Article Title: Locally advanced and unresectable cutaneous squamous cell carcinoma: Outcomes of concurrent cetuximab and radiotherapy
Abstract: Background. Advanced age and immune dysfunction are risk factors for cutaneous squamous cell carcinoma (cSCC) and often render patients with locally-advanced disease medically inoperable or surgically unresectable, but potentially curable with radiotherapy. Concurrent chemotherapy and radiotherapy may not be well tolerated in this population, but another systemic therapy may improve disease control. Objective. Determine the tolerance and efficacy of concurrent cetuximab and radiotherapy (CRT) for patients with locally advanced and unresectable cSCC. Methods. Retrospective analysis of 12 patients treated with CRT for locally advanced and unresectable cSCC. Results. Patients were elderly and 75% had moderate-to-severe comorbidities, while 42% had immune dysfunction. Grades 3-4 adverse events were noted in 83% of patients; 67% required hospital admission for adverse events. Complete and partial response was noted in 36% and 27% (response rate, 64%). Stable and progressive disease was noted in 3 and 1 patients, respectively (disease control rate, 91%). Median progression-free and overall survival were 6.4 and 8.0 months, respectively. Limitations. Retrospective small-cohort, single-institution analysis. Conclusion. Patients selected for CRT were elderly, with comorbidities and immune dysfunction, but treatment responses were observed. Patients selected for this treatment approach have a poor prognosis with limited capacity for therapy; more effective treatment is needed. © 2014 Robert M. Samstein et al.
Keywords: adult; cancer chemotherapy; cancer survival; clinical article; treatment response; aged; middle aged; overall survival; disease course; fatigue; neutropenia; intensity modulated radiation therapy; cisplatin; advanced cancer; cancer combination chemotherapy; drug efficacy; drug safety; systemic therapy; paclitaxel; cancer radiotherapy; outcome assessment; cancer grading; cancer palliative therapy; carboplatin; progression free survival; infection; anemia; mucosa inflammation; clinical assessment; weight reduction; radiation injury; retrospective study; cetuximab; distant metastasis; skin carcinoma; pneumonia; rash; dysphagia; adverse outcome; acne; comorbidity; xerostomia; cancer fatigue; hospital admission; clinical effectiveness; immune deficiency; disease control; drug tolerance; radiation dermatitis; very elderly; human; male; female; article
Journal Title: Journal of Skin Cancer
Volume: 2014
ISSN: 2090-2905
Publisher: Hindawi Publishing Corporation  
Date Published: 2014-07-21
Start Page: 284582
Language: English
DOI: 10.1155/2014/284582
PROVIDER: scopus
PMCID: PMC4129159
PUBMED: 25136458
Notes: Article -- Export Date: 14 August 2017 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Nancy Y. Lee
    550 Lee
  2. Christopher Barker
    116 Barker
  3. Alan Loh Ho
    81 Ho